Clinical & experimental findings

Regulatory recordSupporting passage inspected

Human intravenous DSIP studies exist, but FDA’s 2026 evaluation found insufficient evidence to establish effectiveness for chronic insomnia, narcolepsy or opioid withdrawal. The review did not identify supporting studies for the proposed subcutaneous route.^[1]

Small heterogeneous intravenous studies do not establish reliable sleep benefits from research-market injections.
FDA's INN for DSIP is 'emideltide', a nonapeptide; this is a pre-decisional PCAC briefing, not a final FDA determination.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

2026-09-09 · Reopened the FDA briefing via a working PDF (curl User-Agent workaround); reconfirmed the IV-only evidence base and the 'emideltide' INN identity. Text unchanged; limitations extended. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

FDA review confirms historical intravenous human studies but insufficient clinical evidence for proposed uses or subcutaneous dosing.

Consistent clinically meaningful sleep benefit and subcutaneous pharmacokinetics are unresolved.
Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

FDA July 2026 Pharmacy Compounding Advisory Committee briefing: Emideltide (DSIP)
US Food and Drug Administration. 2026-07. Regulatory document.
Inspected location: Title page/pre-decisional framing p. 1; identity and amino-acid sequence (Figure 5) p. 42; chronic-insomnia conclusion pp. 31-32; opioid-withdrawal and overall conclusions p. 41
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

peptide-fda-dsip-2026: Clinical evidence pp. 31 and 41
July 23–24, 2026 FDA compounding advisory meeting page checked; committee review distinguished from approval.

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.